Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (3y) (2014 - 2026)
Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -3.69% |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 75.30% |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -72.71% |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | -2.64% |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 37.62% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | -75.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.73% |
| Mar 31, 2026 | 26.99% |
| Dec 31, 2025 | 26.01% |
| Sep 30, 2025 | -82.59% |
| Jun 30, 2025 | -79.05% |
| Mar 31, 2025 | 48.49% |
| Dec 31, 2024 | -4.85% |
| Sep 30, 2024 | -8.68% |
| Jun 30, 2024 | -66.48% |
| Mar 31, 2024 | 48.99% |
| Dec 31, 2023 | 55.41% |
| Sep 30, 2023 | 393.53% |
| Jun 30, 2023 | 72.78% |
| Mar 31, 2023 | -43.45% |
| Dec 31, 2022 | -39.57% |
| Sep 30, 2022 | 198.99% |
| Jun 30, 2022 | 87.77% |
| Mar 31, 2022 | 27.27% |
| Dec 31, 2021 | -58.12% |
| Sep 30, 2021 | 2.45% |